Current Therapeutics and Future Perspectives for Treatment of Advanced BRAF V600 mutant Melanoma
نویسندگان
چکیده
Novel Approaches in Cancer Study Current Therapeutics and Future Perspectives for Treatment of Advanced BRAF V600 mutant Melanoma Tiantian Zhang1, Zhe Wang2, Claire Malhotra3, Holly Yin2 Yan Xing3* 1Toni Stephenson Lymphoma Center, Department Hematology Hematopoietic Stem Cell Transplantation, Beckman Research Institute, City Hope, CA, 91010, USA 2High Throughput Screening Core, Share Resources, Duarte, 3Department Medical Oncology Research, *Corresponding author: Xing, Submission: March 15, 2022 Published: April 08, DOI: 10.31031/NACS.2022.07.000653 ISSN:2637-773XVolume7 Issue1
منابع مشابه
Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
The BRAF inhibitor, vemurafenib, has demonstrated improved progression-free and overall survival compared with chemotherapy in a randomized trial, and represents a new standard of care in patients with advanced melanoma harboring a BRAF-V600 mutation. A BRAF-V600 mutation is identified in approximately half of patients with cutaneous melanoma, and is unequivocally a biomarker predictive of prof...
متن کاملBRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma.
INTRODUCTION BRAF inhibition alone has achieved unprecedented efficacy results in patients affected by BRAF-mutated advanced melanoma. Since these findings, it was postulated that dual inhibition of BRAF and other components of the RAS/RAF/MEK/ERK MAPK pathway (such as MEK) would be superior to BRAF inhibition as monotherapy. A series of recent clinical trials have confirmed this hypothesis. ...
متن کاملDabrafenib for treatment of BRAF-mutant melanoma
Melanoma has the highest mortality of all the skin cancer subtypes. Historically, chemotherapy and immunologic therapies have yielded only modest results in the treatment of metastatic melanoma. The discovery of prevalent V600 BRAF mutations driving proliferation makes this oncogenic protein an ideal target for therapy. Dabrafenib, a reversible inhibitor of mutant BRAF kinase, improved response...
متن کاملErratum to “Molecular Targeted Approaches for Advanced BRAF V600, N-RAS, c-KIT, and GNAQ Melanoma”
1 Department of Clinical and Diagnostic Medicine and Public Health, University of Modena and Reggio Emilia, Via del Pozzo 71, 41100 Modena, Italy 2 Department of Dermatology, University of Modena and Reggio Emilia, Via del Pozzo 71, 41100 Modena, Italy 3 Department of Plastic and Reconstructive Surgery, University of Modena and Reggio Emilia, Via del Pozzo 71, 41100 Modena, Italy 4Department of...
متن کاملTreatment of Advanced Cholangiocarcinoma: Current Status and Future Perspectives
Cholangiocarcinoma (CC) is a tumour with a poor prognosis. The treatment of CC is challenging as the tumour is usually diagnosed late and the treatments are not very effective except when complete surgical resection is possible. However in the majority of cases, surgical resection is not possible and palliation is the mainstay of treatment. Currently chemotherapy combining gemcitabine with a pl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Novel approaches in cancer study
سال: 2022
ISSN: ['2637-773X']
DOI: https://doi.org/10.31031/nacs.2022.07.000653